NCT07526493 2026-04-13
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
Clinical Trials
10 trialsNCT06680037 2026-04-07
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT06626919 2026-02-25
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx, Inc.
Phase 1 Recruiting
NCT06220201 2026-02-10
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT07215650 2025-11-17
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Candid Therapeutics
Phase 1 Recruiting
NCT06371040 2025-09-15
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Recruiting
NCT06688435 2025-08-06
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Recruiting
NCT06249438 2025-07-25
CAR-AID
RenJi Hospital
Phase 1 Recruiting
NCT06869278 2025-06-11
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT05828225 2023-04-25
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
Zhejiang University
Phase 1 Recruiting